TriSalus Life Sciences, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a TLSI research report →
About the company
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors.
- CEO
- Mary T. Szela
- IPO
- 2021
- Employees
- 110
- HQ
- Westminster, CO, US
Price Chart
- Market Cap
- $177.80M
- P/E
- -3.33
- P/S
- 3.96
- P/B
- 18.87
- EV/EBITDA
- -7.43
- Div Yield
- 0.00%
- Gross Margin
- 85.07%
- Op Margin
- -62.45%
- Net Margin
- -60.85%
- ROE
- 162.57%
- ROIC
- -47.18%
- Revenue
- $45.15M · 53.41%
- Net Income
- $-39,227,000 · -18.04%
- EPS
- $-1.84 · -47.20%
- Op Income
- $-26,946,000
- FCF YoY
- 54.04%
- 52W High
- $7.95
- 52W Low
- $2.20
- 50D MA
- $3.90
- 200D MA
- $4.83
- Beta
- 0.43
- Avg Volume
- 463.13K
Get TickerSpark's AI analysis on TLSI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 30, 26 | Szela Mary T | other | 3,990 |
| Dec 31, 25 | Szela Mary T | other | 0 |
| Jun 30, 26 | Marshak Richard | other | 561 |
| Dec 31, 25 | Marshak Richard | other | 0 |
| Jun 29, 26 | Marshall Richard Henry | other | 120,000 |
| Jun 29, 26 | Marshall Richard Henry | other | 60,000 |
| Jun 29, 26 | Marshall Richard Henry | other | 0 |
| Jun 29, 26 | Marshall Richard Henry | other | 60,000 |
| Jun 29, 26 | Marshall Richard Henry | other | 25,000 |
| Jun 29, 26 | Marshall Richard Henry | other | 48,000 |
Our TLSI coverage
Recent articles, reports, and earnings notes.
No research on TLSI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate TLSI report →Similar companies
Peers in the same neighborhood.